(Alliance News) - Hutchison China MediTech Ltd said Tuesday it has started its phase 1/1b study of small molecule inhibitor HMPL-689 in patients with advanced relapsed or refractory in the firm at Read More
(Alliance News) - Hutchison China Meditech Ltd on Friday said it has begun a phase 1 study of HMPL-523 as a treatment for immune thrombocytopenia in China, dosing the first patient on Monday last Read More
(Alliance News) - Hutchison China MediTech Ltd on Tuesday said its loss widened in the first half of the year due to expenses, while it has reduced guidance on expenses and cash flow.Shares Read More
(Alliance News) - Hutchison China Meditech Ltd on Wednesday said Prudential PLC held a 5.1% stake in the China-focused drug company.Following a deal on Friday last week, Prudential held in Read More
